Search results for "Radiation therapy"

showing 10 items of 504 documents

Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience.

2020

Objectives: Solitary plasmacytoma (SP) is characterized by a single mass of clonal plasma cells. Definitive RT can result in long-term local control of the SP. Due to the small number of patients and narrow range of doses, phase III randomized trials are lacking. The aim of this study is to further support the potential use of RT for the treatment of SP. Methods: Clinical data of all patients treated for SP at our Institution between 1992 and 2018 were reviewed. A total of 42 consecutive patients were analyzed. Results: The median follow-up was 84.8 months. Radiation dose did not differ significantly as a function of sex, type of SP (solitary bone plasmacytoma or as extramedullary plasmacyt…

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentUrologySolitary plasmacytomaBone NeoplasmsMultiple myeloma; Plasma cell neoplasms; Radical radiotherapy; Solitary plasmacytomaEffective dose (radiation)law.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansMultiple myelomaAgedRetrospective StudiesAged 80 and overHematologyRadical radiotherapyTumor sizebusiness.industryGeneral MedicinePlasma cell neoplasmMiddle Agedmedicine.diseasePrognosisSurvival AnalysisRadiation therapyPlasma cell neoplasm030104 developmental biologyTreatment OutcomeOncologyItaly030220 oncology & carcinogenesisDisease ProgressionFemalePlasma cell neoplasmsNeoplasm Recurrence LocalbusinessMultiple MyelomaSolitary plasmacytomaFollow-Up StudiesPlasmacytomaJournal of cancer research and clinical oncology
researchProduct

Expression of salivary biomarkers in patients with oral mucositis: evaluation by SELDI-TOF/MS.

2016

Objective: This study aims to evaluate changes in proteomic salivary profile of patients with oral mucositis after adjuvant cancer treatments. Materials and Methods: Samples were collected from patients after adjuvant cancer therapies, and were analyzed by means of SELDI/TOF. Patients were separated in two groups: patients affected by mucositis (MUCOSITIS) and patient without mucositis (NO MUCOSITIS). All patients were divided in function of the anticancer treatment: patients who had radiotherapy (MUCOSITIS RADIO), had not radiotherapy (MUCOSITIS NO RADIO), had chemotherapy (MUCOSITIS CHEMO), and those who had not chemotherapy (MUCOSITIS NO CHEMO). Statistical evaluation PCA (Principal Comp…

0301 basic medicineAdultMalemedicine.medical_specialtySalivaPathologymedicine.medical_treatmentGastroenterologySELDI-TOF/MS; biomarker discovery; oral mucositis; saliva; Adult; Aged; Aged 80 and over; Biomarkers; Chemotherapy Adjuvant; Female; Humans; Male; Middle Aged; Neoplasms; Radiation Injuries; Radiotherapy Adjuvant; Saliva; Stomatitis; Spectrometry Mass Matrix-Assisted Laser Desorption-Ionization03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsbiomarker discoverymedicineMucositisHumansRadiation InjurieRadiation InjuriesSalivaGeneral DentistryStomatitisAgedAged 80 and overChemotherapyStomatitisbusiness.industryCancerSELDI-TOF/MSBiomarkerMiddle Agedmedicine.diseaseStomatitiRadiation therapy030104 developmental biologyOtorhinolaryngologyChemotherapy Adjuvant030220 oncology & carcinogenesisSpectrometry Mass Matrix-Assisted Laser Desorption-IonizationBiomarker (medicine)NeoplasmFemaleRadiotherapy AdjuvantbusinessAdjuvantoral mucositiBiomarkersHumanOral diseases
researchProduct

Chemoprevention and therapeutic role of essential oils and phenolic compounds: Modeling tumor microenvironment in glioblastoma

2021

Glioblastoma (GBM) is the most common primary tumor of the central nervous system. Current treatments available for GBM entails surgical resection followed by temozolomide chemotherapy and/or radiotherapy, which are associated with multidrug resistance and severe side effects. While this treatment could yield good results, in almost all cases, patients suffer from relapse, which leads to reduced survival rates. Thus, therapeutic approaches with improved efficiency and reduced off-target risks are needed to overcome these problems. Regarding this, natural products appear as a safe and attractive strategy as chemotherapeutic agents or adjuvants in the treatment of GBM. Besides the increasing …

0301 basic medicineAngiogenesismedicine.medical_treatmentAntineoplastic AgentsMetastasis03 medical and health sciences0302 clinical medicinePhenolsOils VolatileTumor MicroenvironmentAnimalsHumansMedicinePharmacologyBiological ProductsChemotherapyTumor microenvironmentTemozolomideBrain Neoplasmsbusiness.industrymedicine.diseasePrimary tumorRadiation therapy030104 developmental biology030220 oncology & carcinogenesisCancer researchNeoplasm Recurrence LocalStem cellGlioblastomabusinessmedicine.drugPharmacological Research
researchProduct

Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies

2017

Thymoquinone (TQ), the main bioactive component of Nigella sativa, has been found to exhibit anticancer effects in numerous preclinical studies. Due to its multitargeting nature, TQ interferes in a wide range of tumorigenic processes and counteracts carcinogenesis, malignant growth, invasion, migration, and angiogenesis. Moreover, TQ can specifically sensitize tumor cells toward conventional cancer treatments (e.g., radiotherapy, chemotherapy, and immunotherapy) and simultaneously minimize therapy-associated toxic effects in normal cells. In this review, we summarized the adjuvant potential of TQ as observed in various in vitro and in vivo animal models and discussed the pharmacological pro…

0301 basic medicineAngiogenesismedicine.medical_treatmentthymoquinoneReviewPharmacologycancer treatment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAdjuvant therapyMedicinePharmacology (medical)preclinical studiesThymoquinonePharmacologyChemotherapybusiness.industrylcsh:RM1-950Canceradjuvant therapyImmunotherapymedicine.diseaseRadiation therapylcsh:Therapeutics. Pharmacology030104 developmental biologychemistry030220 oncology & carcinogenesisCancer researchbusinessAdjuvantFrontiers in Pharmacology
researchProduct

Knockdown of hnRNPK leads to increased DNA damage after irradiation and reduces survival of tumor cells.

2017

Radiotherapy is an important treatment option in the therapy of multiple tumor entities among them head and neck squamous cell carcinoma (HNSCC). However, the success of radiotherapy is limited by the development of radiation resistances. Heterogeneous nuclear ribonucleoprotein K (hnRNPK) is a cofactor of p53 and represents a potential target for radio sensitization of tumor cells. In this study, we analyzed the impact of hnRNPK on the DNA damage response after gamma irradiation. By yH2AX foci analysis, we found that hnRNPK knockdown increases DNA damage levels in irradiated cells. Tumor cells bearing a p53 mutation showed increased damage levels and delayed repair. Knockdown of hnRNPK appl…

0301 basic medicineCancer ResearchDNA damageCell Survivalmedicine.medical_treatmentmedicine.disease_causeRadiation ToleranceHeterogeneous-Nuclear Ribonucleoprotein KHistones03 medical and health sciences0302 clinical medicineCell Line TumormedicineCarcinomaGene Knockdown TechniquesHumansMutationGene knockdownChemistrySquamous Cell Carcinoma of Head and NeckStem CellsGeneral Medicinemedicine.diseaseHead and neck squamous-cell carcinomaRadiation therapy030104 developmental biologyCell cultureHead and Neck Neoplasms030220 oncology & carcinogenesisGene Knockdown TechniquesCancer researchCarcinoma Squamous CellTumor Suppressor Protein p53DNA DamageCarcinogenesis
researchProduct

Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies

2021

Simple Summary Childhood cancers are mostly of unknown etiology and represent devastating diagnoses. The clinical benefits of steadily increasing tumor control and survival rates are countered by severe and fatal health consequences from genotoxic therapies in long-term survivors of pediatric cancers. Among them, iatrogenic second primary malignancies represent the heaviest burden for the patient. Therefore, particularly in pediatric tumor patients, the reduction of genotoxic treatments and the use of targeted or immune-based oncologic strategies are of high clinical interest. The knowledge of therapy-associated as well as intrinsic risk factors for late sequelae of antineoplastic treatment…

0301 basic medicineCancer Researchmedicine.medical_specialtyetiologymedicine.medical_treatmentPopulationReviewchemotherapyTargeted therapy03 medical and health sciences0302 clinical medicineEpidemiologymedicinechildhood cancerlate-effectseducationIntensive care medicineradiotherapyRC254-282education.field_of_studyChemotherapybusiness.industryCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetargeted therapyPediatric cancerRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisEtiologyepidemiologyimmunotherapybusinesssecond primary malignancyCancers
researchProduct

Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients—Acute Toxicity and Treatment Quality of the Ute…

2015

The Uterus-11 trial was designed to evaluate the role of surgical staging in patients with cervical cancer before primary chemoradiation therapy (CRT). The present report provides the toxicity data stratified by the treatment arm and technique.A total of 255 patients with carcinoma of the uterine cervix (International Federation of Gynecology and Obstetrics stage IIB-IVA) were randomized to either surgical staging followed by CRT (arm A) or clinical staging followed by CRT (arm B). Patients with para-aortic metastases underwent extended field radiation therapy (RT). Brachytherapy was mandatory. The present report presents the acute therapy-related toxicities stratified by treatment arm and …

0301 basic medicineCancer Researchmedicine.medical_treatmentBrachytherapyUterine Cervical NeoplasmsCarboplatinlaw.invention0302 clinical medicineRandomized controlled trialLeukocytopenialawGermanyProspective StudiesStage (cooking)Cervical cancerRadiationRadiotherapy DosageChemoradiotherapyMiddle AgedOncology030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleAdultmedicine.medical_specialtyBrachytherapyAntineoplastic AgentsContext (language use)AdenocarcinomaDisease-Free SurvivalCarcinoma AdenosquamousYoung Adult03 medical and health sciencesmedicineHumansRadiology Nuclear Medicine and imagingAgedNeoplasm Stagingbusiness.industrymedicine.diseaseSurgeryRadiation therapy030104 developmental biologyGynecologyRadiation OncologyLymph Node ExcisionRadiotherapy Intensity-ModulatedCisplatinbusinessChemoradiotherapyInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Diversity of Clinically Relevant Outcomes Resulting from Hypofractionated Radiation in Human Glioma Stem Cells Mirrors Distinct Patterns of Transcrip…

2020

Hypofractionated radiotherapy is the mainstay of the current treatment for glioblastoma. However, the efficacy of radiotherapy is hindered by the high degree of radioresistance associated with glioma stem cells comprising a heterogeneous compartment of cell lineages differing in their phenotypic characteristics, molecular signatures, and biological responses to external signals. Reconstruction of radiation responses in glioma stem cells is necessary for understanding the biological and molecular determinants of glioblastoma radioresistance. To date, there is a paucity of information on the longitudinal outcomes of hypofractionated radiation in glioma stem cells. This study addresses long-te…

0301 basic medicineCancer Researchmedicine.medical_treatmentCell150610Biologylcsh:RC254-282ArticleTranscriptome03 medical and health sciences0302 clinical medicineRadioresistanceGliomamedicineCell growthglioblastomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPhenotypeRadiation therapyradioresistance030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchglioma stem cellsStem cellhypofractionated radiationCancers
researchProduct

Dosimetric Impact of Interfractional Variations in Prostate Cancer Radiotherapy—Implications for Imaging Frequency and Treatment Adaptation

2019

Background and purpose: To analyze deviations of the applied from the planned doses on a voxel-by-voxel basis for definitive prostate cancer radiotherapy depending on anatomic variations and imaging frequency. Materials and methods: Daily in-room CT imaging was performed in treatment position for 10 patients with prostate cancer undergoing intensity-modulated radiotherapy (340 fraction CTs). Applied fraction doses were recalculated on daily images, and voxel-wise dose accumulation was performed using a deformable registration algorithm. For weekly imaging, weekly position correction vectors were derived and used to rigidly register daily scans of that week to the planning CT scan prior to d…

0301 basic medicineCancer Researchmedicine.medical_treatmentRectumlcsh:RC254-28203 medical and health sciencesProstate cancerorgans-at-risk0302 clinical medicineProstateDosimetryMedicineOriginal ResearchDose accumulationdosimetrybusiness.industryimage-guided radiotherapymedicine.diseaseprostate cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenstumor control probabilityRadiation therapyConformity index030104 developmental biologymedicine.anatomical_structureOncologyTreatment delivery030220 oncology & carcinogenesisbusinessNuclear medicineFrontiers in Oncology
researchProduct

2020

Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies such as chemotherapy, radiation, or vaccines, which can stimulate the immune system and recruit antitumor T cells into the tumor bed, may be a relevant strategy to increase the proportion of responding patients. Such an approach still raises the following questions: What are the immunological features modulated by immunogenic therapies that can be critical to ensure not only immediate but also l…

0301 basic medicineChemotherapyTumor microenvironmentbusiness.industrymedicine.medical_treatmentImmune checkpoint inhibitorsCancerGeneral Medicinemedicine.disease3. Good healthRadiation therapy03 medical and health sciences030104 developmental biology0302 clinical medicineImmune systemCancer immunotherapy030220 oncology & carcinogenesisCancer researchmedicinePermissivebusinessCells
researchProduct